2734919-98-1
2734919-98-1
Chemical Structure
Moxifloxacin-d3 hydrochloride
Synonym(s): BAY 12-8039-d3
- CAS No.: 2734919-98-1
- Formula:C21H22D3ClFN3O4
- Molecular Weight:440.91
IUPAC Name: 1-cyclopropyl-6-fluoro-8-(methoxy-d3)-7-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
InChIKey: IDIIJJHBXUESQI-MKOVTIDVSA-N
SMILES: [2H]C([2H])([2H])OC1=C2N(C3CC3)C=C(C(C2=CC(F)=C1N4C[C@@]5([H])[C@@](NCCC5)([H])C4)=O)C(O)=O.Cl
Biological Activity: Moxifloxacin-d3 (hydrochloride) is the deuterium labeled Moxifloxacin hydrochloride. Moxifloxacin hydrochloride is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Moxifloxacin-d3 hydrochloride | Moxifloxacin-d3 (hydrochloride) is the deuterium labeled Moxifloxacin hydrochloride. Moxifloxacin hydrochloride is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxifloxacin (Standard) | 99.72% | Moxifloxacin (Standard) is the analytical standard of Moxifloxacin. This product is intended for research and analytical applications. Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxifloxacin-d4 | 99.9% | Moxifloxacin-d4 is the deuterium labeled Moxifloxacin. Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxifloxacin-d4 hydrochloride | Moxifloxacin-d4 hydrochloride (BAY 12-8039-d4) is the hydrochloride salt form of deuterium labeled Moxifloxacin (Moxifloxacin). Moxifloxacin is an orally active antimicrobial, that can be used in the research of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxifloxacin-d5 | Moxifloxacin-d5 (BAY 12-8039-d5 (free base)) is deuterium labeled Moxifloxacin. Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxifloxacin-d3-1 hydrochloride | Moxifloxacin-d3-1 hydrochloride (BAY 12-8039-d3-1) is a deuterium labeled Moxifloxacin (HY-66011A). Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxifloxacin-13C,d3 hydrochloride | 99.80% | Moxifloxacin-13C,d3 hydrochloride (BAY 12-8039-13C,d3) is 13C and deuterated labeled Moxifloxacin (HY-66011A). Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxifloxacin | 99.75% | Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58(5): p. 379-88. [Content Brief]
- [3]. Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52(5):1697-702. [Content Brief]
